Belite Bio Inc

BLTEStocksPharmaceuticals MajorUnited StatesNasdaqUSD

Price

$158.01

Today

-1.0%

YTD

-0.4%

About

Belite Bio Inc is a clinical stage biopharmaceutical company that develops novel therapies for retinal degenerative eye diseases, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1 (STGD1). The company's lead product candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxins in the eye that cause these diseases. Operating in the healthcare sector, Belite Bio's pipeline of therapies targets unmet medical needs in retinal degenerative eye diseases, which affect millions of people worldwide. Stay up to date on the share price of BLTE by adding it to your eToro watchlist.

Price chart

Closing price history for BLTE (1D candles).

Open positions

Current open positions for this instrument from your live portfolio.

Open positions

Unrealized return

+0.0%

No open positions exist for this instrument at the moment.

Financial insights

Valuation

P/E (TTM)-58.34

P/S (TTM)0.00

P/B (TTM)8.27

Market cap$6.43B

Cap tierMid-cap

Industry avg P/E-7.37

Profitability

Gross marginUnknown

EBIT margin0.00%

Net marginUnknown

ROE-22.10%

ROA-21.60%

Earnings & Revenue

Revenue (TTM)$0.00

Revenue growth (1Y)Unknown

EPS (TTM)-$2.73

Free cash flowUnknown

Total debt$429,000.00

Dividends & Risk

Dividend rate$0.00

Dividend yield0.00%

Beta (5Y)0.67

Employees41

Next earnings9 Nov '26

Trade history

Closed trades

Realized return

+0.0%

No stored closed trades exist for this instrument yet.